Trevena (NASDAQ:TRVN) Receives New Coverage from Analysts at assumed coverage on shares of Trevena (NASDAQ:TRVNFree Report) in a research note released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $9.00 price objective on shares of Trevena in a research report on Tuesday, April 2nd.

View Our Latest Stock Report on Trevena

Trevena Stock Performance

Shares of Trevena stock opened at $0.37 on Monday. The stock’s fifty day moving average is $0.50 and its two-hundred day moving average is $0.58. The company has a market capitalization of $6.78 million, a PE ratio of -0.12 and a beta of 1.10. The company has a quick ratio of 4.66, a current ratio of 4.66 and a debt-to-equity ratio of 8.35. Trevena has a 52 week low of $0.30 and a 52 week high of $3.28.

Institutional Investors Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC acquired a new stake in shares of Trevena, Inc. (NASDAQ:TRVNFree Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned approximately 0.32% of Trevena at the end of the most recent reporting period. 13.56% of the stock is owned by hedge funds and other institutional investors.

About Trevena

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

See Also

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with's FREE daily email newsletter.